Clinical trials: Lymphomas,
Acute Lymphoblastic Leukemia
Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood. Survival rates exceed 90% in children and 75% in adults (aged 18-45 years).
- Trial name
- NCT04843150
- Where
- 2 sites in Denmark
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Recurrent Lymphoma, Refractory Lymphoma
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
- Conditions
- Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours, Central Nervous System
- Trial name
- NCT02343718
- Testing
- Vinblastine, Temsirolimus
- Where
- 6 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Canadian Cancer Trials Group
Diffuse Large B-cell-lymphoma, Classical Hodgkin Lymphoma
Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma
According to the most recent guidelines, total-body imaging techniques are an indispensable element in the staging and post-treatment re-evaluation in patients with lymphoma.
- Trial name
- NCT03042247
- Testing
- FDG PET/TC and FDG PET/MRI
- Where
- 2 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Marco Picardi
Hodgkin Lymphoma
Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma
Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in advanced-stage Hodgkin Lymphoma (HL) patients treated with adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD).
- Trial name
- NCT00877747
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
This study is an Expanded Access Protocol (EAP) of JZP458 in participants with ALL/LBL who are hypersensitive to an E.coli-derived asparaginase (allergic reaction or silent inactivation) and unable to access alternative licensed…
- Trial name
- NCT04943952
- Testing
- Asparaginase Erwinia Chrysanthemi (recombinant)
- Sponsor
- Jazz Pharmaceuticals
Anemia, Multiple Myeloma
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
This is a multi-center open label, randomized phase-3 study with stratification according to diagnosis and baseline serum-EPO level.
- Conditions
- Anemia, Multiple Myeloma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00145652
- Testing
- Neo-Recormon and Venofer
- Where
- Sweden
- Volunteers
- 66 people
- Sponsor
- Sundsvall Hospital
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute…
- Trial name
- NCT06533748
- Testing
- Dexamethasone, Vincristine, Inotuzumab
- Where
- 3 sites in United States
- Volunteers
- 128 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of pralatrexate in combination with bendamustine and total-body irradiation (TBI) followed by a donor stem cell transplant in treating patients with T-cell non-Hodgkin…
- Trial name
- NCT07225985
- Testing
- Bendamustine, Pralatrexate, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Benign Prostatic Hyperplasia (BPH)
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
To evaluate efficacy of BL33 for mild and moderate benign prostatic hyperplasia(BPH).There are trials showing that electroacupuncture on BL33 for mild and moderate BPH is more effective than terazosin.
- Trial name
- NCT01218243
- Testing
- needle
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
ULTRA-V: Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL)
- Trial name
- ULTRA-V (NCT03801525)
- Testing
- Ublituximab, Umbralisib, Venetoclax
- Where
- 50 sites in United States
- Volunteers
- 277 people
- Sponsor
- TG Therapeutics, Inc.
Acute Lymphocytic Leukemia, Leukemia
A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia
The pharmacokinetic behavior of vincristine in pediatric patients has not been well characterized. The present study will obtain detailed information on vincristine pharmacokinetics in patients being treated for standard risk ALL…
- Trial name
- NCT00001689
- Testing
- Vincristine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in…
- Trial name
- NCT06052826
- Testing
- Best Practice, Cognitive Intervention, Comprehensive Geriatric Assessment
- Where
- 4 sites in United States
- Volunteers
- 164 people
- Sponsor
- City of Hope Medical Center
Pediatric NHL
A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin Lymphoma
We hypothesized that polymorphism MTHFR C677T and A1298C should be associated with HD-MTX-related toxicities in children with NHL. Therefore, we aimed to retrospectively explore their relationships in this analysis.
- Trial name
- NCT04283955
- Testing
- High-dose MTX based chemotherapy
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593 alone in the treatment of advanced cancer.
- Trial name
- NCT03389815
- Testing
- WX-0593 Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University
Relapsed/Refractory Mantle Cell Lymphoma
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
In this trial, patients with mantle cell lymphoma will be included, treatment with lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12 cycles, cycle length 28 days.
- Trial name
- PHILEMON (NCT02460276)
- Testing
- Lenalidomide, Ibrutinib, Rituximab
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 50 people
- Sponsor
- Lund University Hospital
Peripheral T Cell Lymphoma
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
This is a non-randomized, open-label, Phase 1b clinical study to evaluate the safety, tolerability and anti-tumor efficacy of SHR0302 as monotherapy in patients with relapsed/refractory peripheral T/NK cell lymphoma.
- Trial name
- NCT05900089
- Testing
- SHR0302
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Leukemia, Lymphocytic, Acute
Adult ALL Treatment at Diagnosis
The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.
- Trial name
- LAL2000 (NCT00537550)
- Testing
- Vincristine, Vincristin, Daunorubicine, Asparaginase, Methotrexate
- Where
- 5 sites in Italy
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Lymphoma, T-Cell, NK-LGL Leukemia
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable.
- Conditions
- Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia
- Trial name
- NCT06530550
- Testing
- PI3K inhibitor
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, Large B-Cell, Diffuse
the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
The main purpose of this study is to explore the sequential therapeutic effect of CD19-targeted and CD20-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Diffuse Large B Cell Lymphoma(DLBCL)
- Trial name
- NCT02737085
- Testing
- Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Southwest Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.